Literature DB >> 8100494

Oxidation of the antihistaminic drug terfenadine in human liver microsomes. Role of cytochrome P-450 3A(4) in N-dealkylation and C-hydroxylation.

C H Yun1, R A Okerholm, F P Guengerich.   

Abstract

The antihistaminic drug terfenadine, alpha-[4-(1,1-dimethylethyl)phenyl]-4-(hydroxydiphenylmethyl)-1- piperidinebutanol (Seldane), is of interest because of its lack of sedative properties. Major routes of metabolism include oxidative N-dealkylation to 4-(hydroxydiphenylmethyl)-piperidine (1) and oxidation of a tert-butyl methyl group to a primary alcohol (2), which is subsequently oxidized to a carboxylic acid. Rates of formation of 1 and 2 varied approximately 30-fold in the 17 human liver microsomal samples examined and were highly correlated with each other, suggesting that the same enzyme may be involved in both oxidations. The rates of formation of 1 and 2 were both correlated with rates of nifedipine oxidation (a marker of cytochrome P-450 (P-450) 3A4) but not with markers for other human P-450s. Microsomal oxidation of (both enantiomers of) terfenadine to 1 and 2 was markedly inhibited by gestodene, a selective mechanism-based inactivator of P-450 3A enzymes but not by any of several other P-450 inhibitors. Antibodies raised against P-450 3A4 could inhibit most of the oxidation of (both enantiomers of) terfenadine to 1 and 2 in a microsomal sample having high catalytic activity but antibodies recognizing other P-450s had no effect. The oxidation of terfenadine to 1 and 2 was catalyzed by purified human liver microsomal P-450 3A4 and by partially purified yeast recombinant P-450 3A4. These results provide evidence that P-450 3A4 (and possibly other P-450 3A enzymes) play a major role in the oxidation of (both enantiomers of) terfenadine to both of its major oxidation products.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100494

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  37 in total

Review 1.  Effects of H1 antihistamines on animal models of QTc prolongation.

Authors:  J Gras; J Llenas
Journal:  Drug Saf       Date:  1999       Impact factor: 5.606

2.  CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.

Authors:  K E Kenworthy; J C Bloomer; S E Clarke; J B Houston
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

Review 3.  Zileuton, a leukotriene synthesis inhibitor in the management of chronic asthma. Clinical pharmacokinetics and safety.

Authors:  L M Dubé; L J Swanson; W Awni
Journal:  Clin Rev Allergy Immunol       Date:  1999 Spring-Summer       Impact factor: 8.667

4.  Interrelationship between substrates and inhibitors of human CYP3A and P-glycoprotein.

Authors:  R B Kim; C Wandel; B Leake; M Cvetkovic; M F Fromm; P J Dempsey; M M Roden; F Belas; A K Chaudhary; D M Roden; A J Wood; G R Wilkinson
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

5.  Rapidly distinguishing reversible and irreversible CYP450 inhibitors by using fluorometric kinetic analyses.

Authors:  Z Yan; B Rafferty; G W Caldwell; J A Masucci
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2002 Oct-Dec       Impact factor: 2.441

6.  Comparison of CYP3A activities in a subclone of Caco-2 cells (TC7) and human intestine.

Authors:  S D Raeissi; Z Guo; G L Dobson; P Artursson; I J Hidalgo
Journal:  Pharm Res       Date:  1997-08       Impact factor: 4.200

Review 7.  Cytochrome P450 2U1, a very peculiar member of the human P450s family.

Authors:  L Dhers; L Ducassou; J-L Boucher; D Mansuy
Journal:  Cell Mol Life Sci       Date:  2017-01-12       Impact factor: 9.261

Review 8.  Effects of the antifungal agents on oxidative drug metabolism: clinical relevance.

Authors:  K Venkatakrishnan; L L von Moltke; D J Greenblatt
Journal:  Clin Pharmacokinet       Date:  2000-02       Impact factor: 6.447

Review 9.  Cytochrome P450s and other enzymes in drug metabolism and toxicity.

Authors:  F Peter Guengerich
Journal:  AAPS J       Date:  2006-03-10       Impact factor: 4.009

Review 10.  Grapefruit juice-drug interactions.

Authors:  D G Bailey; J Malcolm; O Arnold; J D Spence
Journal:  Br J Clin Pharmacol       Date:  1998-08       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.